209 related articles for article (PubMed ID: 29808961)
1. Design, Synthesis, and in vitro Biological Evaluation of 3,5-Dimethylisoxazole Derivatives as BRD4 Inhibitors.
Li X; Zhang J; Zhao L; Yang Y; Zhang H; Zhou J
ChemMedChem; 2018 Jul; 13(13):1363-1368. PubMed ID: 29808961
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis and biological evaluation of 7-methylimidazo[1,5-a]pyrazin-8(7H)-one derivatives as BRD4 inhibitors.
Zhao L; Yang Y; Guo Y; Yang L; Zhang J; Zhou J; Zhang H
Bioorg Med Chem; 2017 Apr; 25(8):2482-2490. PubMed ID: 28314513
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and biological evaluation of benzo[cd]indol-2(1H)-ones derivatives as BRD4 inhibitors.
Feng Y; Xiao S; Chen Y; Jiang H; Liu N; Luo C; Chen S; Chen H
Eur J Med Chem; 2018 May; 152():264-273. PubMed ID: 29730189
[TBL] [Abstract][Full Text] [Related]
4. Targeting epigenetic reader and eraser: Rational design, synthesis and in vitro evaluation of dimethylisoxazoles derivatives as BRD4/HDAC dual inhibitors.
Zhang Z; Hou S; Chen H; Ran T; Jiang F; Bian Y; Zhang D; Zhi Y; Wang L; Zhang L; Li H; Zhang Y; Tang W; Lu T; Chen Y
Bioorg Med Chem Lett; 2016 Jun; 26(12):2931-2935. PubMed ID: 27142751
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and biological evaluation of dihydroquinoxalinone derivatives as BRD4 inhibitors.
Yang Y; Zhao L; Xu B; Yang L; Zhang J; Zhang H; Zhou J
Bioorg Chem; 2016 Oct; 68():236-44. PubMed ID: 27580186
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and biological evaluation of indole-2-one derivatives as potent BRD4 inhibitors.
Xu Y; Zhang XJ; Li WB; Wang XR; Wang S; Qiao XP; Chen SW
Eur J Med Chem; 2020 Dec; 208():112780. PubMed ID: 32883643
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis, and biological evaluation of novel 4,4-difluoro-1-methyl-N, 6-diphenyl-5, 6-dihydro-4H-pyrimido [4, 5-b] [1, 2, 4] triazolo [4, 3-d] [1, 4] diazepin-8-amine derivatives as potential BRD4 inhibitors.
Li J; Zhang W; Qiu Q; Zhou D; Feng Z; Tong Z; Wei J; Huang W; Li J; Qian H; Shi W
Chem Biol Drug Des; 2021 May; 97(5):1117-1128. PubMed ID: 33638254
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and biological evaluation of 3,5-dimethylisoxazole and pyridone derivatives as BRD4 inhibitors.
Rong J; Feng ZZ; Shi YJ; Ren J; Xu Y; Wang NY; Xue Q; Liu KL; Zhou SY; Wei W; Yu LT
Bioorg Med Chem Lett; 2019 Oct; 29(19):126577. PubMed ID: 31421967
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, and biological activity evaluation of a series of novel sulfonamide derivatives as BRD4 inhibitors against acute myeloid leukemia.
Feng Z; Chen A; Shi J; Zhou D; Shi W; Qiu Q; Liu X; Huang W; Li J; Qian H; Zhang W
Bioorg Chem; 2021 Jun; 111():104849. PubMed ID: 33798846
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis and biological evaluation of novel 6-phenyl-1,3a,4,10b-tetrahydro-2H-benzo[c]thiazolo[4,5-e]azepin-2-one derivatives as potential BRD4 inhibitors.
Li Q; Li J; Cai Y; Zou Y; Chen B; Zou F; Mo J; Han T; Guo W; Huang W; Qiu Q; Qian H
Bioorg Med Chem; 2020 Aug; 28(15):115601. PubMed ID: 32631570
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and biological evaluation of indazole-4,7-dione derivatives as novel BRD4 inhibitors.
Yoo M; Yoo M; Kim JE; Lee HK; Lee CO; Park CH; Jung KY
Arch Pharm Res; 2018 Jan; 41(1):46-56. PubMed ID: 29103140
[TBL] [Abstract][Full Text] [Related]
12. Discovery of a series of dihydroquinoxalin-2(1H)-ones as selective BET inhibitors from a dual PLK1-BRD4 inhibitor.
Hu J; Wang Y; Li Y; Xu L; Cao D; Song S; Damaneh MS; Wang X; Meng T; Chen YL; Shen J; Miao Z; Xiong B
Eur J Med Chem; 2017 Sep; 137():176-195. PubMed ID: 28586718
[TBL] [Abstract][Full Text] [Related]
13. Optimization of 3,5-dimethylisoxazole derivatives as potent bromodomain ligands.
Hewings DS; Fedorov O; Filippakopoulos P; Martin S; Picaud S; Tumber A; Wells C; Olcina MM; Freeman K; Gill A; Ritchie AJ; Sheppard DW; Russell AJ; Hammond EM; Knapp S; Brennan PE; Conway SJ
J Med Chem; 2013 Apr; 56(8):3217-27. PubMed ID: 23517011
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and biological evaluation of novel indole derivatives as potential HDAC/BRD4 dual inhibitors and anti-leukemia agents.
Cheng G; Wang Z; Yang J; Bao Y; Xu Q; Zhao L; Liu D
Bioorg Chem; 2019 Mar; 84():410-417. PubMed ID: 30554080
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and biological evaluation of imidazolopyridone derivatives as novel BRD4 inhibitors.
Yang Y; Chen P; Zhao L; Zhang B; Xu C; Zhang H; Zhou J
Bioorg Med Chem; 2021 Jan; 29():115857. PubMed ID: 33191086
[TBL] [Abstract][Full Text] [Related]
16. Discovery of indole-2-one derivatives as BRD4 (BD1) selective inhibitors.
Qiao XP; Wang XT; Wang S; Mu HX; Wang QS; Chen SW
Bioorg Med Chem; 2024 May; 106():117752. PubMed ID: 38749341
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis, and evaluation of novel pyridone derivatives as potent BRD4 inhibitors for the potential treatment of prostate cancer.
Jiang W; Wang X; Shu C; Hou Q; Yang K; Wu X
Bioorg Chem; 2022 Feb; 119():105575. PubMed ID: 34995979
[TBL] [Abstract][Full Text] [Related]
18. 3-Hydroxyisoindolin-1-one derivates: Synthesis by palladium-catalyzed CH activation as BRD4 inhibitors against human acute myeloid leukemia (AML) cells.
Chen P; Yang Y; Yang L; Tian J; Zhang F; Zhou J; Zhang H
Bioorg Chem; 2019 May; 86():119-125. PubMed ID: 30690335
[TBL] [Abstract][Full Text] [Related]
19. Benzoxazinone-containing 3,5-dimethylisoxazole derivatives as BET bromodomain inhibitors for treatment of castration-resistant prostate cancer.
Xue X; Zhang Y; Wang C; Zhang M; Xiang Q; Wang J; Wang A; Li C; Zhang C; Zou L; Wang R; Wu S; Lu Y; Chen H; Ding K; Li G; Xu Y
Eur J Med Chem; 2018 May; 152():542-559. PubMed ID: 29758518
[TBL] [Abstract][Full Text] [Related]
20. Discovery of 3,5-dimethylisoxazole derivatives as novel, potent inhibitors for bromodomain and extraterminal domain (BET) family.
Fang L; Hu Z; Yang Y; Chen P; Zhou J; Zhang H
Bioorg Med Chem; 2021 Jun; 39():116133. PubMed ID: 33862375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
